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Summary  
 
Background. Hepatitis B virus (HBV) is an important cause of chronic viral disease 
worldwide and can be life threatening. While a safe and effective vaccine is widely 
available, 5 to 10% of healthy vaccinees fail to achieve a protective anti-hepatitis B 
surface antigen antibody (anti-HBs) titer (>10mIU/ml). A limited number of studies 
investigated host genetics of the response to HBV vaccine. To our knowledge, no 
comprehensive overview of genetic polymorphisms both within and outside the HLA 
system has been done so far. 
 
Aim. The aim of this study was to perform a systematic review of the literature of 
human genetics influencing immune response after hepatitis B vaccination. 
 
Methods. Literature searches using keywords were conducted in the electronic 
databases Medline, Embase and ISI Web of Science the cut-off date being March 
2014. After selection of papers according to stringent inclusion criteria, relevant 
information was systematically collected from the remaining articles, including 
demographic data, number of patients, schedule and type of vaccine, phenotypes, 
genes and single nucleotide polymorphisms (SNPs) genotyping results and their 
association with immune response to hepatitis B vaccine. 
 
Results. The literature search produced a total of 1968 articles from which 46 
studies were kept for further analyses. From these studies, data was extracted for 19 
alleles from the human leukocyte antigen (HLA) region that were reported as 
significant at least twice. Among those alleles, 9 were firmly associated with vaccine 
response outcome (DQ2 [DQB1*02 and DQB1*0201], DR3 [DRB1*03 and 
DRB1*0301], DR7 [DRB1*07 and DRB1*0701], C4AQ0, DPB1*0401, DQ3, 
DQB1*06, DRB1*01 and DRB1*13 [DRB1*1301]). In addition, data was extracted for 
55 different genes from which 13 extra-HLA genes had polymorphisms that were 
studied by different group of investigators or by the same group with a replication 
study. Among the 13 genes allowing comparison, 4 genes (IL-1B, IL-2, IL-4R and IL-
6) revealed no significant data, 6 genes (IL-4, IL-10, IL-12B, IL-13, TNFA, IFNG and 
TLR2) were explored with inconsistent results and 2 genes (CD3Z and ITGAL) 
yielded promising results as their association with vaccine response was confirmed 
by a replication approach. Furthermore, this review produced a list of 46 SNPs from 
26 genes that were associated with immune response to vaccine only once, 
providing novel candidates to be tested in datasets from existing genome-wide 
association studies (GWAS). 
 
Conclusion. To the best of our knowledge, this is the first systematic review of 
immunogenetic studies of response to hepatitis B vaccine. While this work 
reassesses the role of several HLA alleles on vaccine response outcome, the 
associations with polymorphisms in genes outside the HLA region were rather 
inconsistent. Moreover, this work produced a list of 46 significant SNPs that were 
reported by a single group of investigators, opening up some interesting possibilities 
for further research. 
 
Keywords. Hepatitis B vaccine. Anti-HBs antigen antibody. Immunogenetics. Human 
leukocyte antigen. Single nucleotide polymorphism. 
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Introduction 
 
Hepatitis B virus (HBV) infection represents an important public health problem 
around the world. It is estimated that 2 billion people have been infected and that 
more that 350 million are chronic carriers of the virus (1). The outcome of acute HBV 
infection, which ranges from asymptomatic to fulminant hepatitis, is variable and age 
dependent: roughly 95% of neonates, 20-30% of children and less than 5% of adults 
develop chronic infection (2). Chronic infection may lead to liver cirrhosis and 
hepatocellular carcinoma (HCC). More than 780’000 people die every year due to the 
consequences of HBV infection (1). Nevertheless, the differential outcome of HBV 
infection is still not fully understood and may be explained by host, viral and 
environmental factors. Host genetics of HBV chronic infection was investigated and 
produced interesting results, mainly amongst the Human Leukocyte Antigen (HLA) 
region and the cytokine genes, which are reviewed in some papers (3-10) or meta-
analysis (11-15). 
 
Safe and effective hepatitis B vaccines have been commercially available since 
1982. Most of the vaccines that are used nowadays are derived from recombinant 
DNA technologies while the first vaccines available were obtained by gathering 
hepatitis B surface antigen (HBsAg) from the plasma of chronic HBV carriers (16). 
The World Health Organization (WHO) recommended national childhood 
immunization programs since 1992, and as of today, about 180 countries have 
introduced children and/or adolescent vaccination (17). The vaccine has been 
demonstrated to minimize the incidence of HBV infection, especially when given 
early in life, and to lower the incidence of HCC (18-20), making hepatitis B 
vaccination a precious tool to reduce HBV burden of disease.  
 
An anti-hepatitis B surface antigen (anti-HBs) antibody titer ≥10 mIU/ml measured 1 
to 3 months after administration of the last dose of the primer vaccination is 
considered to be protective (21). Even if the efficacy of the vaccine has been proven 
to be very high, it is estimated that 5-10% of healthy vaccinees fail to reach the 
protective threshold of anti-HBs antibody (17, 22, 23). Apart from the obvious 
immunosuppressive causes of non-response (such as HIV infection, 
immunosuppressive drugs), it has been shown that smoking, high body mass index 
(BMI), male sex, age (more than 30 years old), alcoholism and chronic renal or liver 
failure had a negative impact on hepatitis B vaccine response (23-25). Besides, 
genetic factors seem to have an important role for non-response among healthy 
individuals. The recent advances in genotyping technologies allow investigating the 
heterogeneity in immune vaccine response with a growing interest in predicting 
vaccine response and will possibly permit developing newer effective individualized 
vaccines (26).  
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The first studies investigating genetics of non-response to hepatitis B vaccine started 
in the 1980’s with the analysis of HLA polymorphisms (27). To our knowledge, only 
two meta-analysis have been conducted to date. The first one by Li et al. assessed 
the potential role of HLA class II DRB1 and DQB1 alleles in immune response to 
hepatitis B vaccine by including 15 studies, mainly from Asian populations, and 
highlighted seven DRB1 and three DQB1 alleles that were associated either with 
non-response or with response to hepatitis B vaccine (28). The second one by Cui et 
al. investigated IL4 gene polymorphisms and included a total of eight studies, from 
which five covered response to vaccine (29). However, both meta-analysis 
highlighted several limitations including small sample sized studies, single allele 
analysis in the HLA system, lack of access to the original data of the studies and 
difficulty to assess ethnic subgroups. Yet, no comprehensive overview of genetic 
polymorphisms both within and outside the HLA system has been done to our 
knowledge so far. 
 
In this study, we performed a systematic analysis and review of the available 
literature focusing on the association of genetic polymorphisms with the immune 
response to hepatitis B vaccine. The aim of this work was to establish a 
comprehensive list of genes and SNPs that have an effect or not on the response 
variability to vaccine.   
Material and methods 
 
Literature searches using keywords were conducted in the electronic databases 
Medline (Pubmed), Embase and ISI Web of Science through the program 
EndNoteX7, the cut-off date being March 2014. The keyword searches carried out 
were done with using the combination of “hepatitis B”, “hepatitis B virus”, “hepatitis B 
vaccine”, “HBsAg” and “HBV” with the statement “OR”, the statement “AND” 
combined with the following keywords “immunogenetics”, “genetic susceptibility”, 
“human genetics” and “genetic polymorphism” with the statement “OR”. In addition, 
we performed manual searches according to the reference lists of the included 
articles to identify additional papers related to the topic. 
 
The titles and corresponding abstracts of the articles, as well as other baseline 
information such as author names, date of publishing, the International Standard 
Serial Number (ISSN) were exported into the program EndNoteX7. The list of items 
thus generated was screened by a 3-fold process, first by title, second by abstract 
and third by full-text article reading, in order to get the most relevant material for the 
review, after applying stringent selection criteria as described below. 
 
Articles were excluded from this review when they focused on, (A) HBV-related 
topics other than response to vaccine or susceptibility to chronic hepatitis B (such as 
liver cirrhosis and steatosis, hepatocellular carcinoma, response to treatment, 
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epidemiologic data, pathophysiology of HBV and immunity studies), (B) functional 
susceptibility (such as cellular susceptibility), (C) viral (but not host) genetics, (D) 
other hepatitis viruses (such as HCV, HDV and HAV), (E) pathogen other than HBV, 
diseases other than hepatitis B disease, studies performed in transplanted 
population, animal study, studies focusing on genotyping techniques. Articles in a 
language other than English were not considered. Duplicates were removed. Finally, 
reviews and meta-analysis were also excluded. Studies representing a special 
population such as neonates, HIV co-infected individuals and hemodialysis patients 
were still included. 
 
Because of the unexpected amount of results after the first screening step, we 
decided in a second time to focus on studies concerning response to hepatitis B 
vaccine. The data concerning chronic hepatitis B were set aside and will be analyzed 
in a separate review. 
 
For papers that were selected according to the aforementioned criteria, additional 
information was extracted in order to permit a comparison of one with another. 
Additional data included phenotype tested (non-response, response, mean or median 
anti-HBs titer), response criteria (anti-HBs antibody cut-off levels), type of vaccine 
and vaccine schedules, country of origin of the article, cohort population 
characteristics such as size, ethnicity, age, gender, co-infections and co-morbidities, 
type of analysis (univariate or multivariate), genes and single nucleotide 
polymorphisms (SNPs), major and minor alleles, dominant, recessive or additive 
mode of inheritance, odds ratios or relative risks, 95% confidence interval, p-values, 
and information on multiple testing correction. Family, twin or genome-wide 
association studies (GWAS) were analyzed separately. 
 
For the sake of clarity and to allow a comparison between studies, we admitted that 
all the different schedules and types of vaccine had the same immunogenicity 
(efficacy of plasma-derived and recombinant vaccines are equivalent but routes of 
administration, schedule and dosages may cause variable response in healthy 
individuals (30)). All studies were then grouped together according to gene/SNPs or 
HLA class tested. This produced three lists. The first one was a list of the HLA alleles 
tested at least two times by different papers. The second one was a list of SNPs that 
were studied at least twice by several papers (or within the same paper including a 
replication study) thus permitting comparisons between studies. The third one was a 
list of SNPs analyzed only once by one paper, therefore no comparison was 
achievable.  
 
In order to allow a maximal number of comparisons between studies, we have 
chosen to present the data analyzed with the dominant mode of inheritance (i.e. 
comparison of patients carrying either one or two copies of the minor [mutant], rare 
allele to those carrying two copies of the major [ancestral], most common allele) as a 
baseline in the summary tables. Whenever feasible the statistical analysis presented 
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by each article was redone using Stata/IC 13.1 so as to verify and validate the quality 
of the data presented. Pertinent data resulting from comparisons using the recessive 
or additive mode of inheritance were indicated separately. 
Results 
 
After removal of duplicates, the literature search returned a library of 1968 articles 
(Figure 1). The manual research added 24 papers. From those, 1596 were 
eliminated for non-relevance, based on their title (N=1259), abstract (N=16) or full 
text (N=7). Articles considering chronic versus acute HBV infection were also 
removed (n=314). Forty-six studies were finally selected for further analyses. 
 
Studies’ characteristics 
Among the 46 included studies, 3 were twin studies, two were family studies and one 
was a GWAS (31-36). Studies included in the final analysis had a variable number of 
patients. Eight had more than 1000 participants, four had between 999 and 500 
participants, 27 had between 499 and 100 participants and finally seven studies 
included less than 100 participants. Most of the studies were made among 
Caucasians individuals (N=26, Table 1). Thirteen studies were performed among 
Asian individuals, especially the ones studying the genes out of the HLA system. 
Three studies were done among Africans and four studies included mixed ethnicities 
as the cohort contained both Caucasians and African Americans patients. 
 
The majority of the studies were performed among adults (N=32) and 17 studies 
reported a pediatric population (age <20 years old). Three studies included 
individuals showing past or chronic HBV infection (37-39). One analyzed genetic 
factors associated with both response to vaccine and seroconversion to anti-HBc 
(anti-hepatitis B core antigen antibody), indicating infection despite vaccination (38). 
Only results on response to vaccine are reported. Another one compared vaccine 
induced immunity to natural HBV infection induced immunity as a second outcome 
(the first outcome was immunogenetics of response in non-infected vaccinees and 
only those results are considered) (39). A last one had a mixed population of either 
HBV vaccinees or HBV exposed individuals that were stratified based on their anti-
HBs titer and compared as non-responders versus responders to HBsAg (37). 
Several studies included patients co-infected with HIV-1 (2 studies, (40, 41)) or with 
HCV (2 studies, (37, 39)). Four studies included hemodialysis patients (37, 39, 42, 
43).  
 
Type of vaccines and vaccine schedules varied widely. Thirty-nine papers were 
performed with the recombinant vaccine while 10 studies used the non-recombinant 
plasma-derived hepatitis B vaccine (3 studies included patients vaccinated with either 
the one or the other). Twenty-nine studies used a 3 doses schedule, from which 5 
repeated doses administration in case of non-response, while 9 directly administrated 
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4 initial doses. Six studies included patients who received different schedules (either 
3 or >3 doses). Two studies evaluated response to a booster dose of hepatitis B 
vaccine: the first one consisted in a booster vaccine (1x10ug of HBsAg) about 2 
years after a standard immunization (pre-booster anti-HBs level was not described) 
(44) and the second one in a booster vaccine (1x20ug of HBsAg) about 15 years 
after primary infantile immunization (in individuals with pre-booster anti-HBs titer less 
than 10 mIU/ml) (45). The span of doses ranged from 2 to 40ug of HBsAg. The route 
of administration was predominantly intra-muscular (N=23), but 5 studies reported 
sub-cutaneous or intra-dermal injections (46-50), which are known to be less 
immunogenic routes (30). Two studies reported either intra-muscular or intra-dermal 
injections (38, 51). Sixteen studies did not describe the route of administration. The 
anti-HBs titer was assessed within one month after the last dose administration in the 
majority of the studies (N=28), while in 16 other papers, the time of measurement 
was not specified. 
 
There were different ways to determine the phenotype of vaccine response 
depending on the studies (Table 2). The qualitative way was the most operated, 
especially througha dichotomized way by the comparisons between non-responders 
and responders to hepatitis B vaccine. In another hand, 11 studies considered 
response to vaccine as a continuous trait. Eight studies (31, 32, 38, 47, 51-54) have 
chosen to log-transformed anti-HBsAg antibody titers from which seven reported a 
log normal distribution. One study (44) used percentiles (with a dichotomized 
analysis with a cut-off at percentile 50), one study reported geometric mean titers for 
the whole group of vaccinees (55) and finally one paper described anti-HBs mean 
titers (56).  
 
In 9 papers, HLA allele frequencies in non-responders was compared with the 
frequencies in a non-vaccinated control population and were therefore described as 
unmatched studies (39, 46, 48, 57-62). 
 
HLA alleles associated with non-response to hepatitis B vaccination 
HLA system represents the most investigated field in term of immunogenetics of the 
response to HBsAg vaccine. The oldest studies included in this review are from 1988 
(48, 59, 62). Among the 46 included studies, 33 analyzed the impact of HLA alleles 
on the antibody response to hepatitis B vaccination and 28 of them could be 
compared (1 family study (34), 1 twin study (32), 2 SNPs studies reported below (53, 
63) and 1 GWAS (36) were not considered in this part of the review). Out of these 28 
studies, 18 analyzed HLA class I, 28 HLA class II and 5 HLA class III (complement 
system). HLA-DR locus was the most studied locus in term of vaccine response, 
quickly followed by HLA-DQ locus. In contrast to the extra-HLA studies previously 
exposed, the majority of the present studies were performed among Caucasians (or 
a mix population comprising Caucasian individuals) (N=22). According to the large 
number of allele tested and for the purpose of conciseness, we aimed to present in 
this review the alleles that were reported as significant by at least 2 papers (Table 3). 
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HLA-A2. This allele was studied in 5 Caucasian papers (39, 41, 43, 61, 64). This 
allele was significantly associated with non-response to vaccine in two different 
studies both performed on hemodialysis patients (and HCV co-infected individuals in 
(39)). Those results were not confirmed by the other more recent studies, although 
they had a small number of patients. 
 
HLA-B8. This allele was the most studied allele of the HLA-class I region among 
Caucasians with at least two significant data. A total of six studies (43, 49, 61, 62, 64, 
65) reported this allele but only 2 of them, published before 2000, found out a 
significant association with response to vaccine (43, 62). Those observations need to 
be confirmed in further studies.  
 
HLA-DPB1*0301. Out of the 3 studies that investigated this allele, 2 showed 
significant but divergent data (45, 60, 66). Despite a comparable size, one was 
performed in Caucasians infants with childhood immunization (60) whereas the other 
one on Asian adults who were booster vaccinated (45). Further studies have to 
demonstrate the role of this allele depending on the ethnicity. 
 
HLA-DPB1*0401. Three different studies presented similar significant results among 
Caucasians and Asians, with an association of this allele with the responder 
phenotype (45, 60, 66). The study design of those papers was heterogeneous and so 
this association have to be replicated in other well designed studies. 
 
HLA-DQ2. Amongst 5 studies (39, 43, 58, 64, 65), two reported a significant 
association of this allele with non-response to vaccine but were realized in 
hemodialysis patients (39, 43).  
 
HLA-DQB1*02. Amongst the 6 studies that investigated this allele (35, 40, 41, 50, 
61, 67), 5 described a similar trend than those assessing DQ2 allele and only two of 
them reached the significant statistical threshold (41, 61). Among the 4 studies which 
analyzed DQB1*0201 (44, 60, 66, 68), three reached significance (60, 66, 68). Those 
observations let us expect that DQB1*02 is a good risk factor candidate for non-
response in Caucasians.  
 
HLA-DQ3. One study among Asian individuals and 2 among Caucasian observed a 
significant association between this allele and the responder phenotype (43, 58, 66). 
Another unmatched Asian study failed to demonstrate such an association (48). 
 
HLA-DQB1*03. Three of the five studies that covered this allele found out a 
significant association with response to HBsAg vaccine (41, 44, 61, 66, 67). One of 
them (44), designed with 79 participants whose response to vaccine was considered 
as a continuous trait, reported an association of HLA-DQB1*03 with a titer above the 
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50th percentile. According to those observations, DQB1*03 seems to play a role in 
vaccine response. This role has to be validated in further studies. 
 
HLA-DQB1*06. One study realized among individuals with mixed ethnicities and HIV 
co-infected individuals reported a significant association of DQB1*06 with the 
responder phenotype (the p-value was adjusted for age, gender, ethnicity, vaccine 
schedule and HIV status) (41). Two other studies of Caucasian individuals out of 5 
investigating DQB1*0602 allele reported a significant association with the responder 
phenotype (50, 61). Altogether, those results make HLA-DQB1*06 allele an 
interesting candidate factor for response to vaccine among Caucasians. 
 
HLA-DR1. Of the six studies that covered this allele (43, 46, 50, 59, 64, 66), three 
reported a significant association with response to vaccine (43, 46, 64).  
 
HLA-DRB1*01. Two recent studies with an important number of participants out of 6 
that covered this allele tended to confirm a protective role of DRB1*01 (31, 42). 
Additional studies would be required to confirm this observation. 
 
HLA-DR2. Regarding the other alleles of the HLA-DR locus, only few studies 
investigated DR2 allele. A total of four studies (42, 43, 59, 66) analyzed this allele 
(including one analyzing HLA-DRB1*02 allele) with consistent data for responder 
phenotype even if one of the study didn’t reach significance (66).  
 
HLA-DR3. HLA-DR3, with DRB1*03 and DRB1*0301, was one of the most reported 
allele among the HLA system in this review, mostly among Caucasians (19 papers, 
including one with two cohorts both adult and pediatric (69). A number of studies 
observed significant associations with the non-responder phenotype (35, 39, 40, 42, 
43, 49, 52, 57, 67, 69). Two American studies were performed among HIV co-
infected adolescents (including HIV co-infected individuals) from mix ethnicities 
(Caucasians [including Hispanic individuals] and Afro-Americans) and only one 
reported significant data (40). In this study, the association remained significant when 
tested among 308 HIV negative individuals according to a multivariable model 
comparing non-responders to responders. Through this review, HLA-DR3 seems to 
be one of the most validated risk factor for non-response amongst HBsAg vaccinees. 
 
HLA-DR4. Nine studies covered this allele and only three of them, including 2 
unmatched studies among Asian individuals, reported significant associations with 
divergent effect depending on the ethnicity (43, 46, 48). The seven more recent 
studies among Caucasians that included HLA-DRB1*04 in their analysis didn’t find 
out any significant association (31, 41, 42, 44, 61, 68, 69). HLA-DR4 might have a 
role in the host genetics of Asian individuals and this possible association has to be 
validated by new well-designed studies. 
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HLA-DR5. A total of three articles, published before 2000, related significant but 
divergent data (43, 59, 66). The role of this allele is unclear and has to be determined 
by other modern studies. 
 
HLA-DR6. Two out of the four studies that analyzed this allele reported significant 
results (43, 46). As for HLA-DR5, the role of HLA-DR6 remains unclear in this review, 
reason why this allele has to be assessed in modern studies. 
 
HLA-DR7. HLA-DR7, with DRB1*07 and DRB1*0701, was covered by a total of 
nineteen studies making this allele one of the most reported in the HLA system 
(together with DR3). Ten of these studies demonstrated a significant association with 
non-response (39-41, 43, 52, 57, 61, 62, 66, 69), while only one suggested 
association with the responder phenotype (35). According to the more recent and 
more powerful studies, HLA-DRB1*07 seems to have a negative impact on response 
to hepatitis B vaccine. 
 
HLA-DRB1*11. The association with the responder phenotype was significant in two 
out of the 8 studies that included this allele (31, 67). The more recent studies, but 
with less than 170 participants and with potential confounding factors, didn’t reach 
the statistical significant threshold for this association (41, 68). The role of this allele 
in the Caucasian population has to be clarified in larger studies. No significant 
associations were reported for HLA-DR11 (46, 50, 64). 
 
HLA-DR13. Ten studies investigated the role of either DR13, DRB1*13 or 
DRB1*1301 alleles in response to HBV vaccine, from which 3 reported a significant 
association with the responder phenotype (50, 52, 69). One of them demonstrated 
such association both in an adult and in a children cohort of vaccines (69). A more 
recent study performed on the same cohort of healthy Caucasian adults confirmed an 
association of DRB1*1301 with the responder phenotype (52). Those findings would 
need further validation. 
 
HLA-DR14. Only two studies among the 9 which investigated the implication of either 
DR14 or DRB1*14 or DRB1*1401 on response to vaccine showed significant 
associations (42, 58). The potential association with the non-responder phenotype 
cannot be confirmed by this review. 
 
HLA-DR15. Out of the ten studies that covered DR15 and DRB1*15 alleles (31, 40, 
42, 44, 50, 58, 61, 64, 68, 69), only two related an association with responder 
phenotype with statistical significance (31, 50). The most recent study by Li et al. 
observed a similar trend in a univariate analysis confined to 255 HIV positive 
individuals but without reaching significance (40). Overall, the role of DR-15 allele in 
vaccine response remains unclear. 
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C4AQ0. The only allele of the HLA-class III region to be reported as significant at 
least in two studies was C4AQ0 allele. The six Caucasian studies that included this 
allele demonstrated a marked significant association with the non-responder 
phenotype (35, 43, 52, 57, 60, 67). These data make C4AQ0 one of the best 
candidate allele for vaccine response prediction among Caucasians (see also family 
studies below).  
 
Polymorphisms associated with non-response to hepatitis B vaccination 
Among the 46 included studies, 14 involved gene polymorphisms analysis other than 
HLA alleles and two studies reported SNPs within HLA-B, -DQA1, -DQA2 and -DR 
genes, making a total of 15 papers. Overall, these studies analyzed the role of 
polymorphisms from 55 genes on response to vaccine. Out of the 16 genes that were 
studied in at least two papers, 13 genes contained SNPs that were analyzed at least 
two times and could therefore be compared in term of statistical results (N=19). This 
list of 13 genes included IL10 (6 papers), IL12B (5 papers), TNFA (5 papers), IL4 (5 
papers), IL1B, IL2, IL4R, IL6, IL13, IFNG, TLR2 (2 papers, respectively), CD3Z (1 
paper with replication study) and ITGAL (1 paper with replication study). Details on 
the statistical results of the SNPs that were analyzed in more than one study are 
described in Table 4.  
 
IL10. The most studied gene was IL10, which was analyzed in 7 different papers 
(from which one set forth data regarding haplotypes analysis and so could not be 
used), mainly among Asians. These studies comprised 3 different SNPs. The only 
significant results were reported for rs1800872 (in strong linkage disequilibrium with 
rs1800871) by Lin et al. (70) thru the recessive mode among 278 long term non-
responders (anti-HBs ≤12 mIU/ml) compared to 176 long term responders, with an 
increasing risk for non-response. This observation cannot be confirmed regarding the 
other studies. It is noteworthy that these studies were performed among different 
populations (one with HIV co-infected individuals (41)) and with variable phenotypes.  
 
IL12B. Two IL12B SNPs (rs3212227 and rs17860508) in five different papers were 
available for comparison (37, 41, 54, 71, 72). One study, which analyzed the effect of 
rs3212227 on the median anti-HBs titer among 139 healthy children of 1 year old, 
reported a significantly lower titer regarding the dominant mode (54). Other larger 
studies failed to show a significant association for this polymorphism according to a 
qualitative model. One study showed an association of rs17860508 with non-
response (41). This study was performed among healthy and HIV positive 
adolescents from mix ethnicities and even if the results were adjusted for age, 
gender, ethnicity and HIV status, they have to be treated with caution. The other 
study (71) with more cases and controls reported a similar trend (recessive mode), 
even if the analyzed phenotypes of response were different.  
 
IL4. Five different papers studied three polymorphisms of IL4 gene (41, 55, 71-73). 
The most reported was rs2243250, for which 2 studies realized among Asians found 
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significant but divergent data (55, 72). 2 studies reported a second SNP (rs2070874), 
and only the Asian study observed a significant association of this polymorphism with 
poor response to vaccine (72). The third SNP (rs2243248), studied in two papers, 
didn’t show significant results. The two polymorphisms rs2243250 and rs2070874 
might play a role in immune response to HBsAg in Asian individuals. 
 
TNFA. One SNP (rs1800629) in TNFA gene was analyzed in five papers (41, 54, 55, 
72, 74). Only one of them reported a significant positive effect on median anti-HBs 
titer (54). Another more recent study, with a similar number of participants but from a 
different ethnicity (Asians), didn’t confirm the effect of this SNP among anti-HBs titer 
(continuous trait) (55). 
 
IFNG. Two studies covered the same SNP in this gene (38, 71). Hennig et al. 
performed their study among a cohort of 662 Africans from the Gambia and observed 
a significant positive effect of rs2069727 on the Geometric Mean peak anti-HBs Titer 
(GMT). Due to a small number of non-responders, the authors didn’t carry out a 
case-control study. No significant effect was reported by the other study. 
 
IL1B. Two studies that measured rs16944 in IL1B didn’t observe any significant 
impact of this polymorphism (55, 72).  
 
IL2. Two studies failed to detect any association between response to vaccine and 
rs2069762 (41, 72). 
 
IL4R. One polymorphism within IL4R gene (rs1801275) was analyzed by two papers 
with different ethnicities and different phenotypes but didn’t show significant data (41, 
55). 
 
TLR2. One SNP in TLR2 gene, rs3804100, was assessed in two Asian studies (41, 
73). The significant association with non-response observed in the first, small 
powered study (73) failed to be confirmed in a larger one (72). 
 
CD3Z. A group investigated a SNP in CD3Z (rs12133337), in a two-step replication 
study performed among a large Asian population (75). The authors found out a 
positive association with poor response to hepatitis B vaccination. Further studies are 
needed to confirm the potential role of this SNP. 
 
ITGAL. Two SNPs in this gene (rs4243232 and rs2230433) were explored in a two-
fold analysis in an African population, first among 662 vaccinees and in a second 
time among 393 vaccinees (38). Even if the two polymorphisms showed a significant 
positive association with a higher anti-HBs titer (continuous trait), only data 
concerning rs2230433 returned significant in the second fold phase. This observation 
would require validation in other large population studies. 
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A total of 46 SNPs from 26 genes (3 genes that were cited previously and 23 other) 
were significantly associated only once with response to hepatitis B vaccine (14 of 
them were reported as haplotypes). A total of 41 SNPs in 29 genes (7 genes 
previously cited and 22 other) were not associated with the outcome of HBsAg 
vaccination (Table 5). 
 
Family, twin studies and GWAS. 
We identified three twin studies among our literature review. Höhler et al. 
investigated heritability of HBsAg vaccine response in 382 Caucasians twins (192 
monozygotic and 190 dizygotic) vaccinated with a 3 fold 20ug recombinant HBsAg 
vaccine and found out that 60% of the phenotypic variance could be explained by 
additive genetic and 40% by non-shared environmental effects (31). The authors 
suggested that 40% of this genetic contribution is affected by MHC-genes (mainly 
HLA-DRB1* locus) and 60% by non MHC-genes. Another study in the same cohort of 
twins related that approximately 25% of heritability of vaccine response is determined 
by variability in the IL-10 promoter (rs1800896, rs1800871 and rs1800872) (33). 
However, we previously reported that data from studies that analyzed those three 
SNPs were rather inconclusive (see above and Table 4). Newport et al. observed a 
heritability reaching 77% for hepatitis B vaccine response among 207 twin pairs from 
the Gambia (32). This heritability was higher than the other studied vaccines (oral 
polio (60%), tetanus (44%) and diphtheria (49%)). 
 
Two family studies were recorded (34, 35). Kruskall et al. reported the association of 
homozygous individuals for the extended HLA-B8-SC01-DR3 haplotype with the non-
response phenotype by analyzing 43 members of ten Caucasians families 
immunized with plasma-derived HBsAg and suggested that response was inherited 
in a dominant mode. De Silvestri et al. showed through the analysis of families of 27 
non-responders that C4AQ0 allele, previously associated with the non-responder 
phenotype (see above), was almost always transmitted to non-responders, but 13 of 
the 27 families with a non-responder baby were not carriers of C4AQ0 allele. 
Although not statistically significant, this data tends to further support the implication 
of C4AQ0 in response to HBV vaccine. 
 
Only one GWAS appeared in this literature review (36). This 2-stage GWAS was 
performed among Indonesians from Batam and the surrounding islands near 
Singapore. In the first stage, 1638 vaccinees were genotyped for a total of 455508 
SNPs and in the second stage 1931 individuals were genotyped for a total of 1706 
SNPs leading to the identification of three SNPs within the HLA complex. These are 
rs3135363 in HLA-DR locus (which appeared to be the most significant contributor to 
antibody response, even after adjusting for the effects of other independent loci) and 
rs9267665 in the HLA-class III region, both associated with poor response to vaccine 
and rs9277535 in the HLA-DP locus (HLA-DPB1) associated with good response. 
Those three SNPs were not reported in the other studies included in this literature 
research, but the HLA loci corresponding to these polymorphisms (HLA-DR, HLA-
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DPB1 and HLA-class III) have been associated with variation in vaccine 
responsiveness by the HLA studies included in this systematic review. The same 
association with good response was observed for HLA-DPB1 alleles (see above). 
 
Finally, this literature research disclosed one study that investigated haptoglobin 
gene phenotype with the immune response after hepatitis B vaccine (56). 
Haptoglobin is coded by 2 different genes and could therefore be described by three 
polymorphisms: Hp 1-1, Hp 2-1, Hp 2-2. This study performed among 100 healthy 
Caucasians vaccinated with a recombinant hepatitis B vaccine reported that subjects 
with a 2-2 haptoglobin phenotype produced significantly lower anti-HBs titer 
compared to the other phenotypes. To our knowledge, this is the only study relating 
this gene in the immune response to hepatitis B vaccine. 
Discussion 
 
This review focused on the human genetics of the immune response to hepatitis B 
vaccination and included a total of 46 studies disclosing a list of 55 candidate genes 
and another list of 19 alleles in the Major Histocompatibility Complex (MHC) that may 
influence the outcome after HBsAg vaccination. To our knowledge, this is the first 
systematic review covering genetic factors both outside and within the HLA system 
and limited to hepatitis B vaccine since others reviewed them separately or for 
several vaccines at the same time (76-78).  
 
Firstly, our systematic review shows that the most studied genetic region regarding 
the response to hepatitis B vaccine is the HLA region. A total of 33 studies among 
the 46 included in our work focused on MHC complex. Data presented are consistent 
(Table 4) and reflects the crucial role of this complex in antigen processing. Among 
the HLA alleles, this review found out 9 alleles that were firmly associated with 
immune response after hepatitis B vaccination (validated by at least three different 
studies and with coherent association): DQ2 (DQB1*02 and DQB1*0201), DR3 
(DRB1*03 and DRB1*0301), DR7 (DRB1*07 and DRB1*0701) and C4AQ0 
associated with non-responder phenotype; DPB1*0401, DQ3, DQB1*06, DRB1*01 
and DRB1*13 (DRB1*1301) associated with responder phenotype. Furthermore, two 
studies reported significant polymorphisms located in HLA-DQA1, -DQB1 and -DRA 
genes. One GWAS reported three significant polymorphisms in HLA-DR locus, HLA-
DPB1 gene and HLA-class III region, and those results tend to further confirm the 
previously reported associations. None of these SNPs were analyzed twice. Our 
results are in accordance with those previously reported in other reviews (4, 76, 77, 
79). The present work has the advantage of collecting an important number of HLA 
studies (not gathered in previous reviews) and thus presenting a better 
comprehensive overview of the different alleles in terms of association with the 
responsiveness to hepatitis B vaccine. 
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Secondly, this work shows that polymorphisms studied at least by two papers 
demonstrate inconsistent data while many interesting candidate genes are reported 
but not validated (Table 2 and 3). Our work summarizes an extensive list of SNPs 
associated with response to HBsAg vaccination from individual studies. These 
polymorphisms can now be systematically tested in datasets such as the one built in 
our institution (more than 700 healthcare workers vaccinees), thereby opening some 
interesting possibilities for further research.  
 
Among the 55 genes covered by the included studies, 19 polymorphisms from 13 
genes have been analyzed more than once. Those genes could be classified in three 
categories. 4 genes including IL1B, IL2, IL4R and IL6 revealed no significant data; 6 
genes including IL4, IL10, IL12B, IL13, TNFA, IFNG and TLR2 were explored with 
inconsistent results, as significant and non-significant associations were observed 
and sometimes even reverse associations; 2 studies identified interesting genes 
including CD3Z and ITGAL which were confirmed by a replication approach (38, 75), 
but both investigations were conducted by the same research group. One meta-
analysis found that three SNPs among IL4 gene, rs2243250, rs2070874 and 
rs2227284, were associated with a good response to hepatitis B vaccine among 
Asian individuals but not among Caucasians (29). In our review, data concerning 
rs2243250 and rs2070874 polymorphisms were inconsistent and rs2227284 SNP 
was studied only once in (72), thus not permitting statistical comparisons. 
 
Finally, this literary search shows that a great majority of the HLA studies were 
performed among Caucasians population while the majority of the papers reporting 
genes outside the MHC region were realized in Asians individuals. There are 
relatively few studies analyzing African populations although Africa is one of the 
important prevalent regions for HBV endemicity (Table 1). Hennig et al. reviewed 
host genetic factors influencing HBV infection, liver cancer and vaccine response 
with a focus on Africa, and these studies are included in our review (80). 
 
This literary search was firstly designed to highlight papers covering either HBV 
infection or vaccine response, thereby making this research less specific to the 
vaccine response. This bias was partially corrected with manual searches through 
the pertinent papers collected. Like most systematic reviews, this work has other 
important limitations. These are linked to the heterogeneity of the studies in term of 
population (age, gender, ethnicity, co-morbidities), control population (vaccinated or 
not), vaccine types and schedules, phenotypes compared and definitions (non-
responders, high-responders, etc.), genotyping (inconsistencies in polymorphisms 
denomination, quality check for sequencing, etc.), statistical analysis (absence of 
reporting for Bonferroni’s correction for example) and quality. Three of the included 
studies screened more than 100 genes, using an approach similar to that of GWAS 
(38, 51, 63). One of them did not mention Bonferroni’s correction (38). Despite the 
fact that HBsAg vaccination represents an easier and reproducible way to study 
immunogenetics of HBV infection, we found only a few papers using a properly 
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comparable way of vaccine administration and outcome analysis. A standardized 
way of vaccination against HBV would allow more pertinent and more robust studies 
and meta-analysis. Nevertheless, we tried to be as strict as possible regarding the 
inclusion criteria of the articles in order to end up with a list of studies that would be 
as comparable as possible. 
 
Altogether, this master thesis is the first systematic review of immunogenetic studies 
of response to hepatitis B vaccine within and out the HLA system. Despite the fact 
that HLA alleles seems to be well-known influencing factors, this work shows that 
only little is known about the role of polymorphisms in other genes, including cytokine 
genes and surface receptors genes. While polymorphisms studied more than once 
are rather inconsistent, many polymorphisms still not validated may have an 
interesting role in immune response after hepatitis B vaccination. 
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Table 1. Patients’ ethnicity and country of origin. 
 
Country 
Number of articles per Ethnicity 
Caucasian Asian African Mix Total 
Germany 6 − − − 6 
Italy 4 − − − 4 
USA 2  − − 41 6 
UK 2 − − − 2 
Belgium 2 − − − 2 
Brazil 1 − − − 1 
France 1 − − − 1 
Greece 1 − − − 1 
Hungary 1 − − − 1 
India 1 − − − 1 
Iran 1 − − − 1 
Poland 1 − − − 1 
Spain 1 − − − 1 
Sweden 1 − − − 1 
Turkey 1 − − − 1 
China − 4 − − 4 
Taiwan − 4 − − 4 
Japan − 3 − − 3 
Indonesia − 1 − − 1 
Singapore − 1 − − 1 
Gambia − − 3 − 3 
Total 26 13 3 4 46 
 
1 This study contained mixed population of Caucasians and African Americans. 
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Table 2. Phenotypes of response to vaccine according to studies. 
 
  
Number of 
groups 
Phenotypes Anti-HBs cut-off level(s) Study 
Qualitative 
2 
NR vs R 
10 mIU/ml 
 (37, 39, 41-43, 
49, 52, 65, 69) 
1 mIU/ml1  (45) 
2000 RIA units  (34) 
<10 and >100 mIU/ml 
 (50, 63, 64, 68, 
73) 
NR vs HR <10 and >1000 mIU/ml  (66) 
LTLR vs LTR2 10 mIU/ml  (70, 72) 
LR vs HR 10-99 and >1000 mIU/ml   (71, 75) 
R vs HR 10-1000 and >1000 mIU/ml  (55, 74) 
NR vs controls3 
NR: <3 mIU/ml  (59) 
NR: <10 mIU/ml (60, 61) 
NR: <10 RIA units  (57) 
ULR: <20 mIU/ml4  (58) 
NR: S/N <2 RIA units  (46) 
NR: S/N <9.9 SRU  (62) 
NR: ? (48) 
3 
NR, MR and HR 
<10, 10-1000 and >1000 
mIU/ml 
 (40) 
hR, R and HR 
<100; 100-1000 and >1000 
mIU/ml 
 (36) 
4 tNR, SR, LR and R 
<104, >1004, 11-40 and >100 
mIU/ml 
 (35, 67) 
Qantitative 
(continuous 
trait) 
− 
standardized 
anti-HBs log titer  
− 
(31-33, 38, 47, 
51, 53, 54) 
− 
anti-HBs mean 
titer 
−  (55) 
− 
geometric mean 
titer 
−  (56) 
2 percentiles ≤50% vs >50%1 (44) 
 
Abbreviations: aNR: absolute non-responder, anti-HBs: anti-hepatitis B surface antigen antibody, HR: 
high responder, hR: hypo-responder, IU: international units, LTNR: long term non-responder, LTR: 
long term responder, LR: low responder, NR: non-responder, R: responder, RIA: radioimmuno assay, 
S/N: sample counts per minute divided by mean of negative controls, SR: slow responders, SRU: 
sample ratio units, tNR: true non-responder, ULR: ultimate low responder. MR: moderate responder, 
1 
Anti-HBs titer after booster dose 
2 
Anti-HBs titer was measured ca 6 years (72) and ca 17 years (70) after neonatal immunization 
3
 Controls are unvaccinated individuals 
4
 Anti-HBs titer after revaccination 
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Table 3. Genetic studies of immune response to hepatitis B vaccine for HLA alleles reported as significant at least twice.  
 
HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
HLA class I 
          
HLA-A A2 Stachowski (43) 1995 153 34/119 matched C _ _ <0.01 
  
Peces (39) 1997 333 13NRs/43Rs/277 matched and unmatched C 7.10
2 
_ <0.05 
  
McDermott (61) 1997 217 86/131 unmatched C _ _ NS 
  
Wang (41) 2004 164 79/85 matched mix _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
HLA-B B8 Weissman (62) 1988 1051 22/1029 unmatched C _ _ <0.02 
  
Varla-Leftherioti 
(49) 
1990 169 68/101 matched C _ _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <10E-15 
  
McDermott (61) 1997 217 86/131 unmatched C _ _ NS 
  
Das (65) 2004 30 15/15 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
HLA class II 
          
HLA-DP DPB1*0301 Martinetti (60) 1995 638 26/612 unmatched C 2.90 _ 0.03 
  
Desombere (66) 1998 146 46/100 matched C 0.75
2
 _ NS 
  
Wu (45) 2013 681 171/510 matched A 0.29 0.12-0.67 0.004 
 
DPB1*0401 Martinetti (60) 1995 638 26/612 unmatched C 0.24 _ 0.009 
  
Desombere (66) 1998 146 46/100 matched C 0.18
2
 _ <0.01 
  
Wu (45) 2013 681 171/510 matched A 0.28 0.11-0.70 0.009 
HLA-DQ DQ2 Hsu (58) 1993 700 23/677 unmatched A 1.90
2
 _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <10E-13 
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HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
  
Peces (39) 1997 333 13NRs/43Rs/277 matched and unmatched C 4.20
2
 _ <0.05 
  
Das (65) 2004 30 15/15 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DQB1*02 McDermott (61) 1997 203 86/117 matched C 5.65
2
 _ <0.001 
  
Langö-Warensjö 
(50) 
1998 122 53/69 matched C _ _ NS 
  
Martinetti (67) 2000 92 16/76 matched C 3.03 1.24-7.39 NS 
  
De Silvestri (35) 2001 71 31/40 matched C 2.20 _ NS 
  
Wang (41) 2004 164 79/85 matched mix 2.55 _ 0.002
3 
  
Li (40) 2009 335 97HRs/160MRs/78NRs matched mix 1.45
4 
0.93-2.22 0.1
5 
 
DQB1*0201 Martinetti (60) 1995 558 34/524 unmatched C 2.80 _ 0.02 
  
Desombere (66) 1998 146 46/100 matched C 4.78
2
 _ 0.001 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Amirzargar (68) 2008 58 12/46 matched C 2.94 1.04-8.33 0.04 
 
DQ3 Hsu (58) 1993 700 23/677 unmatched A 0.20
2
 _ 0.001 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <10E-6 
  
Desombere (66) 1998 146 46/100 matched C 0.37 _ <0.01 
 
DQw3 Watanabe (48) 1988 2073 19/1988 unmatched A _ _ NS 
 
DQB1*03 Wang (41) 2004 164 79/85 matched mix _ _ NS 
 
DQB1*0301 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Desombere (66) 1998 146 46/100 matched C 0.07
2
 _ <0.005 
  
Martinetti (67) 2000 92 16/76 matched C 0.00 0.00-0.33 0.02 
  
Lindemann (44) 2002 79 _ _ C _ _ 0.03 
 
DQB1*0301/03
04 
Langö-Warensjö 
(50) 
1998 122 53/69 matched C _ _ NS 
 
DQB1*03011 Amirzargar (68) 2008 58 12/46 matched C 0.85 0.17-3.57 1 
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HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
 
DQB1*06 Wang (41) 2004 164 79/85 matched mix 0.72
6 
_ 0.02
3 
 
DQB1*0602 McDermott (61) 1997 217 86/131 unmatched C 0.25
2
 _ <0.001 
  
Desombere (66) 1998 146 46/100 matched C 0.44 _ NS 
  
Langö-Warensjö 
(50) 
1998 122 53/69 matched C _ _ 0.01 
  
Lindenmann (44) 2002 79 _ _ C _ _ NS 
  
Amirzargar (68) 2008 58 12/46 matched C 0.31 0.01-2.56 0.45 
HLA-DR DR1 Krämer (59) 1988 2524 25/2499 unmatched C 1.30 _ NS 
  
Hatae (46) 1992 153 33/120 unmatched A 0.00
2
 _ 0.02 
  
Stachowski (43) 1995 153 34/119 matched C _ _ 0.02 
  
Desombere (66) 1998 146 46/100 matched C 0.09
2
 _ NS 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C NC NC <0.05 
 
DRB1*01 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C 0.47 0.25-0.87 0.02 
  
Höhler (69) 1998 126 73/53 matched C _ _ NS 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.02 
  
Wang (41) 2004 164 79/85 matched mix _ _ NS 
 
DRB1*0101 Amirzargar (68) 2008 58 12/46 matched C 0.40 0.02-3.45 0.7 
 
DR2 Krämer (59) 1988 2524 25/2499 unmatched C 0.27 _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <0.01 
  
Desombere (66) 1998 146 46/100 matched C 0.65
2
 _ NS 
 
DRB1*02 
Caillat-Zucman 
(42) 
1998 415 114/301 matched C 0.55 0.30-0.99 0.05 
 22 
HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
 
DR3 Krämer (59) 1988 2524 25/2499 unmatched C 2.80 _ NS 
  
Weissman (62) 1988 1167 22/1145 unmatched C _ _ NS 
  
Varla-Leftherioti 
(49) 
1990 169 68/101 matched C _ _ 0.02 
  
Hsu (58) 1993 700 23/677 unmatched A 1.50
2
 _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <10E-10 
  
Dondi (57) 1996 400 30/370 unmatched C 3.48
2
 _ 0.002 
  
Peces (39) 1997 333 13NRs/43Rs/277 
matched and 
unmarched 
C 3.40
2
 _ <0.05 
  
Desombere (66) 1998 146 46/100 matched C 2.55
2
 _ NS 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ NS 
 
DRB1*03 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C 2.42 1.46-3.96 0.001 
  
Höhler (69) 1998 126 73/53 matched C _ _ 0.03 
  
Höhler (69) 1998 118 62/56
7 
matched C _ _ 0.002 
  
De Silvestri (35) 2001 71 31/40 matched C 4.10 _ 0.007 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Wang (41) 2004 164 79/85 matched mix _ _ 0.1
3 
  
Li (40) 2009 335 97HRs/160MRs/78NRs matched mix 1.72
4
 1.02-2.94 0.04
5, 8 
 
DRB1*0301 Martinetti (67) 2000 92 16/76 matched C 8.18
 
2.55-26.3 0.003 
  
Höhler (52) 2002 126 73/53 matched C _ _ 0.04 
  
Amirzargar (68) 2008 58 12/46 matched C 2.08 0.47-9.09 0.26 
 
DR4 Watanabe (48) 1988 2073 19/1988 unmatched A 2.57
2
 _ <0.05 
  
Weissman (62) 1988 1167 22/1145 unmatched C _ _ NS 
  
Krämer (59) 1988 2524 25/2499 unmatched C 1.49 _ NS 
  
Hatae (46) 1992 153 33/120 unmatched A 3.02
2
 _ 0.05 
 23 
HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
  
Hsu (58) 1993 700 23/677 unmatched A 1.50
2
 _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <0.01 
  
Desombere (66) 1998 146 46/100 matched C 0.77
2
 _ NS 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DRB1*04 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C _ _ NS 
  
Höhler (69) 1998 244 135/109 matched C _ _ NS 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.2 
  
Wang (41) 2004 164 79/85 matched mix _ _ NS 
  
Amirzargar (68) 2008 58 12/46 matched C 2.08 0.47-9.09 0.3 
 
DR5 Krämer (59) 1988 2524 25/2499 unmatched C 2.95 _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <0.001 
  
Desombere (66) 1998 146 46/100 matched C 0.08
2
 _ <0.05 
 
DR(w)6 Krämer (59) 1988 2524 25/2499 unmatched C 0.97 _ NS 
  
Hatae (46) 1992 153 33/120 unmatched A 0.10
2
 _ 0.048 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <0.01 
  
Desombere (66) 1998 146 46/100 matched C 1.04
2
 _ NS 
 
DR7 Weissman (62) 1988 1167 22/1145 unmatched C _ _ <0.02 
  
Krämer (59) 1988 2524 25/2499 unmatched C 0.86 _ NS 
  
Hsu (58) 1993 700 23/677 unmatched A 1.60
2
 _ NS 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <0.001 
  
Dondi (57) 1996 400 30/370 unmatched C 2.24
2
 _ 0.03 
  
Peces (39) 1997 333 13NRs/43Rs/277 matched and C 5.10
2
 _ <0.05 
 24 
HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
unmarched 
  
Desombere (66) 1998 146 46/100 matched C 4.39
2
 _ <0.005 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DRB1*07 McDermott (61) 1997 217 86/131 unmatched C 3.01
2
 _ <0.001 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C _ _ NS 
  
Höhler (69) 1998 126 73/53 matched C _ _ 0.002 
  
De Silvestri  (35) 2001 71 31/40 matched C 0.90 _ <0.05 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.5 
  
Wang (41) 2004 164 79/85 matched mix 5.18
6
 _ 2.0E-4
3, 9 
  
Amirzargar (68) 2008 58 12/46 matched C 1.47 0.44-4.76 0.6
 
 
DRB1*0701 Höhler (52) 2002 126 73/53 matched C 7.49 2.51-22.3 3.0E-4
10 
  
Li (40) 2009 335 97HRs/160MRs/78NRs matched mix 1.79
4
 1.07-2.94 0.025
5, 11 
 
DR(w)11 Hatae (46) 1992 153 33/120 unmatched A 11.9
2
 _ 0.4
 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DRB1*11 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C _ _ NS 
  
Höhler (69) 1998 244 135/109 matched C _ _ NS 
  
Martinetti (67) 2000 92 16/76 matched C 0.00 0.00-0.41 0.047 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.01 
  
Wang (41) 2004 164 79/85 matched mix _ _ 0.08
3 
 25 
HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
  
Amirzargar (68) 2008 58 12/46 matched C 0.32 0.01-2.63 0.45 
 
DR13 Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DRB1*13 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Höhler (69) 1998 126 73/53 matched C 0.10
2
 _ 1.0E-4 
  
Höhler (69) 1998 118 62/56
7 
matched C _ _ 0.04 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.7 
  
Wang (41) 2004 164 79/85 matched mix _ _ NS 
 
DRB1*1301 
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ <0.05 
  
Höhler (52) 2002 126 73/53 matched C 0.14 0.04-0.51 0.003
10 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Amirzargar (68) 2008 58 12/46 matched C 0.46 0.02-4.00 0.7 
 
DR14 Hsu (58) 1993 700 23/677 unmatched A 4.40
2
 _ 0.01 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ NS 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DRB1*14 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C 3.46 1.39-8.60 0.008 
  
Höhler (69) 1998 244 135/109 matched C _ _ NS 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.7 
 
DRB1*1401 Amirzargar (68) 2008 58 12/46 matched C 0.95 0.04-10.0 1 
 
DR15 Hsu (58) 1993 700 23/677 unmatched A 0.70
2
 _ NS 
  
Langö-Warensjö 
(50) 
1998 121 53/68 matched C _ _ <0.01 
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HLA type HLA subtype First author Year N Cases/controls
1 
 
Ethnicity 
Non-response to vaccine 
OR 95% CI P 
  
Albayrak (64) 2011 68 25/43 matched C _ _ NS 
 
DRB1*15 McDermott (61) 1997 203 86/117 matched C _ _ NS 
  
Caillat-Zucman 
(42) 
1998 415 114/301 matched C _ _ NS 
  
Höhler (69) 1998 244 135/109 matched C _ _ NS 
  
Lindemann (44) 2002 79 _ _ C _ _ NS 
  
Höhler (31) 2002 382 _ _ C _ _ 0.03 
  
Amirzargar (68) 2008 58 12/46 matched C 0.29 0.01-2.38 0.3 
  
Li (40) 2009 335 97HRs/160MRs/78NRs matched mix 0.62 0.35-1.07 0.09
12 
HLA class III 
          
C4 C4AQ0 Martinetti (60) 1995 224 34/190 unmatched C 6.51 _ 1.0E-4 
  
Stachowski (43) 1995 153 34/119 matched C _ _ <0.001 
  
Dondi (57) 1996 400 30/370 unmatched C 3.25
2
 _ 0.001 
  
Martinetti (67) 2000 49 9/40 matched C 18.0 2.44-145 0.02 
  
De Silvestri  (35) 2001 71 31/40 matched C 9.10 _ 2.0 E-5 
  
Höhler (52) 2002 126 73/53 matched C 3.60 1.44-9.00 0.05
10 
 
Abbreviations: HLA: human leukocyte antigen, HR: high responder, MR: moderate responder, N: total number of patients included in the study, NR: non-
responder, OR: odds ratio, CI: confidence interval, P: p-value, R: responder. 
The studies that were comparing the frequency of a HLA allele in a non-responders group to an unvaccinated control group were considered as unmatched 
studies.  
When required, OR, RO or RR were reversed for the sake of comparison. 
1 
Unless otherwise indicated and when studies are matched, cases are non-responders and controls are responders to HBV vaccine 
2 
Relative risk (RR) 
3 
Adjusted for ethnicity, gender, age, HBV vaccine product group, and HIV-1 serostatus 
4 
Proportional odds ratio (pOR) 
5 
Adjusted for age, ethnicity, gender and HIV serostatus 
6 
Relative odds (RO) 
7 
Cohort of children that were immunized at 3, 4 and 5 months of age 
8 
Multivariable model without individuals being HIV positive (308 patients, NR vs. HR+MR): OR=2.38, 95% CI 1.20-4.76, P=0.013. 
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9 
Multivariable logistic regression analysis RO=4.89, 95% CI 1.50-15.93, P=0.008 
10 
Logistic regression analysis 
11 
Multivariable model without HIV positive individuals (308 patients, NR vs. HR+MR): OR=2.78, 95% CI 1.37-5.56, P=0.005 
12 
Univariate analysis, confined to HIV positive individuals (N=255) 
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